Riskpilot← Back to searchSign inGet full accessKlamer Scientific AB
ABActiveOrg 5569043713Linnégatan 36 BEngineering activities and related technical consultancy · NACE 7112Est. 20120 employees
Revenue 2024
SEK 94K
+21% vs 2023
EBITDA margin
76.6%
+22% vs 2023
Equity ratio
79.5%
Financial strength
Net profit 2024
SEK 60K
+22% vs 2023
| Revenue | SEK 94K | +21% |
| EBITDA | SEK 72K | +22% |
| Net profit | SEK 60K | +22% |
| Total assets | SEK 726K | +10% |
| Equity | SEK 577K | +12% |
| Employees | 0 | — |
Legal name
Klamer Scientific AB
Org number
5569043713
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
20 september 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Aktiebolaget ska bedriva bioteknisk forskning och utveckling av läkemedel, natur- och hälsoprodukter samt produktion och marknadsföring och försäljning av detsamma samt därmed förenlig verksamhet. Bolaget skall även bedriva konsult- samt utbildningsverksamhet inom dessa områden, samt handel med värdepapper och fastigheter samt därmed förenlig verksamhet. Bolaget skall även utveckla programvaror och webbtjänster.
Address
Linnégatan 36 B
Phone
+46704828669
Email
lidia.zajde@comhem.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 474 | 0 | 33 | 339 | 171 | 78 | 94 |
| Staff expenses | — | — | — | — | — | — | — | — | −9 | — |
| EBITDA | −7 | −5 | −14 | 442 | −25 | 21 | 289 | 145 | 59 | 72 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | −0 |
| EBIT | −7 | −5 | −14 | 442 | −25 | 21 | 289 | 145 | 59 | 72 |
| Net financials | — | — | — | — | — | — | — | — | 3 | 4 |
| Profit before tax | 5 | −5 | −14 | 442 | −25 | 21 | 289 | 145 | 62 | 76 |
| Tax | −5 | −0 | −0 | −59 | −0 | −0 | −45 | −20 | −13 | −16 |
| Net profit | 0 | −5 | −14 | 383 | −25 | 21 | 244 | 125 | 49 | 60 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 149 | 138 | 123 | 567 | 383 | 349 | 533 | 662 | 661 | 726 |
| Equity | 76 | 71 | 57 | 440 | 246 | 99 | 342 | 468 | 517 | 577 |
| Long-term debt | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 |
| Short-term debt | 8 | 2 | 1 | 62 | 72 | 186 | 126 | 129 | 79 | 84 |
| Total debt | 73 | 67 | 66 | 127 | 137 | 251 | 191 | 194 | 144 | 149 |
EBITDA margin
76.6%
This company
15.8%
Market median
+385% vs market
20152024
Equity ratio
79.5%
This company
38.2%
Market median
+108% vs market
20152024
Return on equity
10.4%
This company
18.4%
Market median
+43% vs market
20152024
Net profit margin
63.8%
This company
8.1%
Market median
+688% vs market
20152024
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
20152024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Klamer Scientific AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Artur Klamer | Board of Directors | 0 companies |
| David Andreas Klamer | Deputy Board Member | 0 companies |
| Lidia Zajde | Chairman | 0 companies |